Genedx Holdings Corp. · NASDAQ:WGS
Genedx — 41st Annual JPMorgan Healthcare Conference 2023
25 slides from Genedx's conference presentation, Jan 12, 2023
Slide 1: 41st Annual JPMorgan Healthcare Conference
41st Annual JPMorgan Healthcare Conference January 12, 2023 San Francisco One Test: Miss Less. Discover More. GeneDx (Nasdaq: WGS) Katherine Stueland President and Chief Executive Officer
Slide 2: Disclaimer
2 Disclaimer This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, fo
Slide 3: Our mission: deliver personalized and actionable health insights
Our mission: deliver personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery.
Slide 4: The problem: lack of genomic data and connectivity with EMR
The problem: lack of genomic data and connectivity with EMR Symptoms Tests are ordered More tests But no answers Try new doctors But no records Suboptimal care Waiting for answers that come too late Patients miss milestones Waiting for a proper diagnosis More tests And more spending Years of missed
Slide 5: Our Solution: Genomic Data + Clinical Insights = Better Health
Our Solution: Genomic Data + Clinical Insights = Better Health
Slide 6: Built by GeneDx: Genomic interpretation platform
>400K clinical exomes > 1 million DNA extractions >400 gene discovery publications Built by GeneDx: Genomic interpretation platform Since our inception more than 20 years ago, we believe we offer the most definitive genomic analysis in the industry, borne from over a decade of constructing our propr
Slide 7: Built by Sema4: Centrellis health insights platform
Built by Sema4: Centrellis health insights platform We’ve spent over 10 years developing the most sophisticated dataset in the industry, complete with custom algorithms and more accurate analyses 3.1 million patient health records 8 million disease diagnoses 47 million phenotypes 20 years of records
Slide 8: Best of both creates a seamless solution
Best of both creates a seamless solution Sequence once Expand the use of and deliver best in class whole exome/genome analysis & interpretation Combine clinical + genomic data Match structured clinical and genomic data and supplement with disease models to drive insights Providing actionable insight
Slide 9: The strategy is working: Preliminary 2022 Financial Results
9 The strategy is working: high volume and revenue growth, expanding gross margins, reduced cash burn Excluding revenues and costs from the exited business activities, we expect GeneDx to: • Generate pro forma revenues between $170-173 million in 2022, a 37-40% increase from 2021 • Produce pro forma
Slide 10: 2023 Guidance
v Revenues between $205-220 million for full year 2023 Expanded adjusted gross margin profile 2023 and beyond Inclusive of servicing obligations of the exited business activities, total cash burn in 2023 between $130-145 million, a >50% reduction year-over-year Use of net $95-110 million in cash in
Slide 11: Driving growth and expanding markets
Driving growth and expanding markets
Slide 12: Quickly growing into a significant opportunity
Quickly growing into a significant opportunity Conservatively, our diagnostic testing total addressable market is ~$30 billion1 Newborn Screening: $10B Eventual inclusion of genetics in screening programs Underdeveloped Solution for Sema4 Adults: $16B Rapidly expanding into cardio and neuro to repla
Slide 13: Starting with rare disease and pediatrics
Starting with rare disease and pediatrics •>7000 individual diseases affecting 10% of the total population • • 400 million people worldwide • • 50% of people affected by rare diseases are children • • 700 medicines in development – same as oncology with regulatory pathway via Orphan Drug Act
Slide 14: Today's strategy expedites diagnoses, saves money per patient
NICU Patient Test ordered Today’s strategy expedites diagnoses, saves money per patient with rapid exome and genome sequencing Starting with the most vulnerable patients Rapid results ✓ Patient retention ✓ Patients connected ✓ Healthier outcomes ✓ $6,8002 savings per diagnosis when tested at first t
Slide 15: Rapidly growing and loyal customer base
+500 With a rapidly growing and loyal customer base Geneticist Neonatologist Pediatrician Neurologist Cardiologist Hospital Lab Director • Leveraging decades of earned trust amongst expert geneticists to expand into incremental call points and use cases • •94% of pediatric specialists in the U.S. wh
Slide 16: Emerging guidelines and medical policies underpin rapid growth
Emerging guidelines and medical policies underpin rapid growth ACMG Practice Guideline published July 2021: “Strong recommendation based on the available evidence to support the use of ES/GS as either a first- (or second-) line test in patients …. ES/ GS demonstrates clinical utility for the patient
Slide 17: Transforming the standard of care
Transforming the standard of care October 27, 2022 Sema4 | GeneDx Announces Results from Phase 1 of Seq First Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns October 5, 2022 Sema4 | GeneDx To Provide Whole Genome Sequencing and Interpretation Services
Slide 18: Tomorrow's strategy: sequence once, analyze forever
Tomorrow’s strategy delivers the promise of sequence once, analyze forever, deliver actionable information Patient’s lifetime A single test at or near birth with continuous data reinterpretation throughout a patient’s lifetime could lead to earlier diagnosis and better outcomes Sequence once at birt
Slide 19: Miss Less. Discover More. Our unparalleled interpretation platform.
Miss Less. Discover More. Our unparalleled interpretation platform.
Slide 20: Delivering fewer uncertain findings
Delivering fewer uncertain findings, critical for expanding utilization Return results Analyze variants Analyze phenotypes Improve Interpretation Engine • Fewer uncertain findings lead to improved clarity for clinicians and patients • More expertly curated disease-causing variants vs. public data se
Slide 21: The snowball effect of accumulated GeneDx data
The snowball effect of accumulated GeneDx data identifies more pathogenic findings that others miss Lab A GeneDx Panels leave patients behind. Exome and genome do not.
Slide 22: Untapped partners: biopharma
Untapped partners: biopharma In 2020 alone, more than half (55%) of novel new drug and biological approvals were orphan drugs for rare diseases.
Slide 23: Biopharma research offerings: Find, Understand, Platform
FIND 0 - 3 year focus UNDERSTAND 1 - 5 year focus PLATFORM Long Term M ar ke t O pp or tu ni ty FIND Recurring services model for identifying Rare Disease patients for clinical trial recruitment or delivery of targeted Rx UNDERSTAND Reports w/analytics leveraging clinicogenomic data in Rare Disease
Slide 24: Experienced management team
Experienced management team with decades of leadership in genetics, data science, healthcare Gustavo Stolovitzky Chief Science Officer Katherine Stueland Chief Executive Officer Jennifer Brendel Chief Commercial Officer Matthew Davis Chief Technology & Product Officer Kevin Feeley Chief Financial Of
Slide 25: One test. There's no one better.
One test. There's no one better.
GeneDx Holdings — 41st Annual JPMorgan Healthcare Conference 2023 on 6ix